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The occurrence of intolerable side effects in 
patients undergoing chemotherapy is still 
a major clinical hurdle. Finding tumor-spe-
cific therapy and exploiting the differences 
between normal cells and tumor cells has led 
to strategies targeting oncogenic mutations or 
the deficiency of tumor suppressor pathways 
in cancers. Alternatively, focusing efforts to 
protect normal cells from the side effects of 
chemotherapy has gained much interest, and 
harnessing cell cycle checkpoints to target 
tumor cells while sparing normal cells is an 
attractive strategy.
Contrary to achieving drug synergism 
when targeting tumor cells, one hopes to 
achieve drug “antagonism” on normal cells in 
a proposed strategy, termed “cyclotherapy.”1 
The concept requires the use of two drugs, the 
first to arrest the normal cells and the second, 
to kill only cycling (tumor) cells (Fig. 1). The 
high frequency of p53 mutations in human 
cancers presents an opportunity for selectively 
targeting the p53-deficient tumors using s- or 
M-phase poisons, by activating a checkpoint 
arrest only in the normal cells. indeed, several 
recent studies demonstrate that p53 activation 
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protects normal cells from the toxicity of drugs 
acting in the s-phase or M-phase, including 
Ara-C,2 taxol,3 Aurora kinase inhibitors4 and 
Polo-like kinase inhibitors.5 The therapeutic 
window, in this case, is defined by (1) the 
toxicity of p53 activation in normal tissues, (2) 
the specificity of the “first” drug for p53 activ-
ity and (3) the effectiveness of the “second” 
drug in inducing p53-independent apoptosis. 
exploring various combinations of p53-acti-
vating drugs and cell cycle-specific poisons 
may help to clarify the importance of each 
criteria. ingeborg et al.6 recently performed 
a systematic screening of 16 drug combina-
tions of p53 activators and s- or M-phase 
poisons for the protection of wild-type p53 
cells while rendering selective toxicity against 
p53-deficient cells. Remarkably, all of the 
tested p53-activating drugs (nutlin-3, a small-
molecule antagonist of MDM2, Actinomycin 
D, Tenovin-6, Leptomycin B) antagonize the 
activity of microtuble-targeting compounds 
(vinblastine, vinorelbine) and antimetabolites 
(Ara-C and gemcitabine) in normal primary 
human fibroblasts, thus protecting them. They 
further explored the specificity of the observed 
drug antagonism for wild-type p53 cells by 
testing the same combinations on cell lines 
deficient for p53 functions. interestingly, differ-
ent classes of p53-activating drugs have varied 
outcomes in mutant p53 cells. while nutlin 
and Actinomycin D, as expected, do not induce 
any arrest in mutant p53 cells, Tenovin-6 and 
Leptomycin B activated a cell cycle arrest that 
protected the mutant p53 cells against vinca 
alkaloids. Curiously, the cell cycle arrest only 
partially protected the mutant p53 cells from 
Gemcitabine and Ara-C. The study revealed 
that the specificity of the p53-activating drug 
for wild-type p53 is critical for cyclotherapy 
against p53-mutant tumors. Understanding 
what invokes a p53-independent cell cycle 
arrest in response to Tenovin-6 and Leptomycin 
B may help to prescribe the use of these drugs 
as chemoprotectants in another context.
Before p53-based cyclotherapy can be 
used in the clinic, one would like to know (1) 
the consequences of p53 activation in various 
normal tissues, (2) the outcome of p53 activa-
tion by different drugs, which may differen-
tially effect p53-dependent gene transcription, 
either favoring cell cycle arrest, apoptosis or 
Figure 1. Harnessing p53-dependent cell cycle arrest to protect normal cells and render selective drug toxicity to p53 mutant cells. sequential drug 
therapy using a p53-activating drug that results in cell cycle arrest in normal cells and a second drug that targets only proliferating cells (any s- or 
M-phase specific poisons), results in selective killing of p53-deficient tumor cells while sparing normal cells.© 2012 Landes Bioscience.
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The complex process of semi-conserva-
tive DnA replication involves a mechanism 
whereby the leading and lagging strands with 
opposite polarity serve as templates for con-
certed synthesis of complementary base pairs.1 
Lagging-strand synthesis creates discontinu-
ous Okazaki fragments that require timely 
processing of the 5′ flaps, so that adjacent 
nascent DnA strands are ligated together to 
insure genomic stability. while the genetic and 
molecular requirements of Okazaki fragment 
maturation have been studied in much detail, 
the precise temporal and spatial relationship 
of lagging-strand processing to sister chro-
matid cohesion remains unclear.2 The newly 
replicated daughter duplex DnA molecules 
(i.e., the sister chromatids) become tethered 
during DnA replication and remain paired 
in order to permit proper segregation of the 
chromosomes to respective poles during 
mitosis and nuclear division. elegant genetic 
studies in yeast have implicated posttransla-
tional modification of cohesins (specialized 
protein complexes responsible for tethering 
sister pairs) by Ctf7/eco1 acetylase as a key 
regulatory step in the process, enabling cohes-
ins to perform their function in capturing the 
newly synthesized sister chromatids. Previous 
work suggested that genetic and physical 
interactions among the yeast acetyltransferase 
Ctf7/eco1, helicase Chl1, Flap endonuclease 
(Fen1) and accessory replication factors [e.g., 
RFC (clamp loader) and PCnA (clamp)] play 
an integral role in cohesion establishment. 
Based on these pieces of evidence, several 
models to explain the relationship between 
replication fork dynamics and sister chromatid 
cohesion have been proposed; however, our 
understanding of the precise timing of cohesin 
acetylation and the passage of the replication 
fork machinery has remained murky at best. 
Given the importance of proper chromosome 
segregation for chromosomal stability and the 
suppression of developmental disorders and 
tumorigenesis, a comprehensive understand-
ing of the molecular acrobatics involved in 
sister chromatid cohesion is highly important.
in a recent study, the temporal relationship 
between sister chromatid establishment and 
lagging-strand synthesis was illuminated.3 The 
authors have elucidated the link between the 
catalytic functions of DnA unwinding, flap 
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senescence, and (3) the right dosage of drugs 
to use for chemoprotection. High drug doses 
may induce other p53-independent cytotoxic 
effects that trigger DnA damage, synergizing 
with the activity of p53 to induce apoptosis 
instead. The observation that nutlin can sup-
press neutropenia,5 a common side effect in 
chemotherapy, in mice treated with Polo-like 
kinase inhibitors provides great optimism.
should the selection of new small mol-
ecules activating p53 for chemoprotection, 
be based on their selectivity for cell cycle 
arrest (over apoptosis)? nutlin, for example, 
has low dose potency; however, because of its 
specificity for p53 activity and its low toxicity 
on normal tissues, it seems like a good can-
didate as a chemoprotectant. Apart from the 
p53 pathway, perhaps other oncogenic path-
ways may be considered for the cyclotherapy 
approach? For example, inhibition of the eGF, 
MeK or Pi3-K prevents proliferation in normal 
cells but not in some tumor cells. UCn-01, a 
CHK kinase inhibitor, also prevents cell cycle 
progression and suppresses the toxicity of 
Topotecan in bone marrow.7 Finally, establish-
ing in vivo models to test for potential drug 
combinations in cyclotherapy would be excit-
ing in the future.
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Figure 1. interplay between acetylation, replication fork dynamics and cohesion establishment 
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Preserving genome stability is critically impor-
tant for cell survival. DnA is under continuous 
attacks from damaging agents that threaten 
proper replication and gene expression. The 
DnA damage response (DDR) coordinates 
repair throughout the cell cycle.
Cyclin-dependent kinase-9 (CDK9) has 
been implicated in double-strand break (DsB) 
repair and suppression of DnA:RnA hybrid 
(R-loop) formation. Moreover, recently it 
has been shown that it is important in the 
response to replication stress induced by HU 
and aphidicolin.1,2
CDK9, together with cyclins T1/T2, forms 
the positive transcription elongation factor-
b (P-TeFb). CDK9 acts mainly through phos-
phorylation of ser2 within the C-terminal 
repeat domain (CTD-s2ph) on RnA poly-
merase ii and subsequent co-transcriptional 
histone modifications and mRnA processing. 
CTD-s2 phosphorylation leads to histone H2B 
monoubiquitination (H2Bub1) and histone H3 
trimethylations.1
UBe2A (yeast Rad6 homolog) serves as the 
e2 and complexes with e3 ubiquitin ligase 
formed by RnF20/40 to monoubiquitinate 
H2B. CDK9-induced CTD-s2 phosphorylation 
recruits the RnF20/40 through interaction with 
wAC protein.3 interestingly, in the absence of 
CTD-s2ph, some H2Bub1 still persists com-
pared with CDK9 knockdown, suggesting 
additional modes of regulation.4
This report investigates the interaction 
between CDK9 and UBe2A. The authors show 
that CDK9 interacts with UBe2A and phosphor-
ylates it in vitro and in vivo, similar to what has 
been found in yeast. Moreover, they explore the 
mechanisms for modulation of UBe2A activ-
ity and demonstrate that UBe2A phosphoryla-
tion affects the enzymatic activity but not its 
interaction with binding partners. Knockdown 
of CDK9 affects not only H2B but also PCnA 
monoubiquitination in the Uv damage 
response, potentially affecting the DnA dam-
age tolerance (DDT) and/or the Fanconi anemia 
(FA) pathways. interestingly, cyclin T1 seems 
to contribute to this activity. Collectively, this 
report shows that the role of P-TeFb-mediated 
phosphorylation is more complex that initially 
realized and contributes to understanding of 
CDK9 in the response to the DnA damage.5
yeast cells have two CTD-s2 kinases, Bur1 
and Ctk1.6 CDK9 was considered the only 
mammalian homolog fulfilling both roles. 
Cyclin K has been implied to be the important 
player for the different pathways. However, 
recent studies have characterized a new kinase 
complex, CDK12/CyclinK.7 More and more 
evidence points at CDK12 as the functional 
homolog of Ctk1. Both play a role in DDR; 
processing and acetylation, which supports a 
model of cohesion deposition and establish-
ment that occurs after the passage of the 
replication fork, similar to how genomic DnA 
becomes chromatinized. This is a significant 
advance from an earlier and very popular 
model of sister chromatid cohesion predicted 
that Ctf7/eco1 acetylated cohesin proteins 
before the encounter by the DnA replication 
fork, which was thought to permit fork pro-
gression and the proper cohesion state for sis-
ter chromatid tethering (for review, see ref. 2). 
instead, the genetic evidence presented by the 
skibbens lab supports a model whereby cohe-
sion establishment is temporally coupled to 
lagging-strand processing.3 in support of the 
genetic proof, Rudra and skibbens went on to 
show that both Ctf7/eco1 and Chl1 are associ-
ated with the lagging-strand processing nucle-
ase Fen1. Altogether, the experimental results 
implicate a post-fork establishment model 
that is analogous to how histone protein com-
plexes are deposited onto newly synthesized 
sister chromatids and become posttranslation-
ally modified to confer epigenetic status.
The discovery from the skibbens lab that 
cohesion establishment is closely orchestrated 
with Okazaki fragment processing prompts a 
new line of inquiry about the control of flap 
processing by acetylation and its dual pur-
pose for proper sister chromatid cohesion and 
replication fidelity in eukaryotes (Fig. 1). The 
catalytic activity of human Fen-14,5 and a func-
tionally related endonuclease known as Dna24 
have been shown to be modulated by p300 
acetylation, which suggested a model for 
creating long flap intermediates to promote 
genomic stability and suppress mutagenesis. 
Given evidence that ChlR1 is implicated in the 
genetic disorder warsaw Breakage syndrome 
and that the human homolog of yeast Chl16 
interacts with the RFC complex and Fen1,7 
it will be informative to determine if acetyl-
transferases such as the human orthologs 
esco1 and esco2, the latter mutated in the 
cohesinopathy Roberts syndrome,8 and per-
haps other acetyltransferases (e.g., p300) are 
master regulators of lagging-strand synthesis 
that not only affect replication fidelity and 
genomic stability, but also sister chromatid 
cohesion. Coordination of sister chromatid 
cohesion establishment with lagging strand 
synthesis may also involve replication fork 
stabilization by the Timeless-Tipin protein 
complex implicated in replication checkpoint.9 
Defects in the efficient coupling of lagging-
strand synthesis to sister chromatid cohesion 
may contribute to the chromosomal instabil-
ity characteristic of age-related diseases and 
cancer.
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Autophagy is a fundamental cellular process in 
which surplus or modified cellular components, 
from individual proteins to whole organelles, 
are degraded in the lysosomes. Autophagy 
prevents the accumulation of random molecu-
lar damage in long-lived structures, particularly 
mitochondria, and more generally provides 
a means to reallocate cellular resources from 
one biochemical pathway to another. 
Consequently, it is commonly upregulated in 
conditions where a cell is responding to stress 
signals, such as starvation, oxidative stress and 
exercise-induced adaptation.
while autophagy is a process of damage 
repair, senescence might be viewed as a state 
of damage limitation, occurring when the level 
however, their contributions are quite distinct 
(Fig. 1). CDK12 maintains genomic stability 
by direct regulation of the expression of ATR, 
BRCA1 and FANCI.7 However, CDK9 can act 
through both direct and indirect mechanisms. 
First it co-immunoprecipitates with the ATR-
ATRiP-claspin complex, acting in a common 
pathway in response to HU.2 On the other 
hand, it is a potential global chromatin modu-
lator due to its induction of H2Bub1 modifica-
tion.1 H2Bub1 could orchestrate chromatin 
changes to allow repair mechanisms onto the 
DnA in response to specific DnA changes.
it is still not clear whether both CDK9 
and CDK12 act in parallel or are activated 
in response to different stress signals. 
interestingly, it seems that there are at least 
two forms of ser2 marks, and they respond 
distinctly to depletion of the two kinases.7 
Moreover, whether cyclin K is bound exclu-
sively to CDK12 or if it also interacts with CDK9 
under specific conditions remains to be veri-
fied. This study provides the first evidence that 
cyclin T1 contributes to DDR. it will be interest-
ing to test whether the other cyclins (K and T2) 
can also play a role in the Uv damage response. 
This is particularly interesting in the light of the 
recent study showing importance of cyclin K in 
response to camptothecin and ionizing radia-
tion but not MMs (a Uv mimetic).8
Both CDK9 and CDK12 can potentially 
contribute to cancer. This could be especially 
important in the response to inter-strand DnA 
cross-links in the FA pathway, where CDK9 can 
contribute by PCnA modification and CDK12 
can directly affect the FAnCi and FAnCD2 
expression. encouragingly, studies in gastric 
and breast cancers have shown that the CDK9 
inhibitor flavopiridol can increase the effi-
ciency of Mitomycin C in the induction of 
apoptosis.9 Combining the CTD-s2ph inhibi-
tors with radiotherapy or chemotherapy could 
refine the present strategies to fight cancer.
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Figure 1. schematic representation of CDK9/CDK12 influence on DnA damage response. CDK9 
interacts with cyclins T1/T2 and possibly also cyclin K. CDK12 binds cyclin K. Both kinase/cyclin 
complexes can phosphorylate RnA polymerase ii C-terminal on serine 2 (CTD s2ph). There seem 
to be at least 2 forms of ser2 marks, possibly distinct in response to the action of the two kinases. 
CDK12 affects genomic stability through the regulation of gene expression of DnA damage 
responsive genes (ATR, BRCA1, FAnCi). CDK9 can have direct and indirect effects on genomic 
stability. CDK9 can directly form a complex with ATR/ATRiP. Moreover, CDK9 phosphorylates CTD 
(which recruits e3 ligases -RnF20/40) and e2 (UBe2A), both required for H2B monoubiquitination 
(H2Bub1). This modification plays a critical role in chromatin structure modulation, potentially 
affecting the response to different damaging stresses: double-strand breaks (DsB), DnA-RnA 
hybrid structures (R-loops), single-strand breaks (ssB) and interstrand DnA crosslinks (iCLs). UBe2A 
phosphorylation can also directly affect ssB and iCLs.
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or nature of damage detected is likely to be 
irreparable. Triggered either by genotoxicity 
registered via p53 or via a secondary pathway 
involving p16inK4a, the senescent state is char-
acterized by cell cycle arrest, hypertrophy and 
flattening along with changes in a panel of 
genetic and proteomic biomarkers, especially 
the lysosomal protein β-galactosidase.© 2012 Landes Bioscience.
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The current papers by Peiqing sun and col-
laborators1 and by Mikhail Blagosklonny and 
collaborators2 add new important pieces to 
the role of the mTOR pathway in senescence 
and longevity.
Filling the Gaps
The ser/Thr-kinase mTOR is a main metabolic 
sensor activated by the presence of nutrients, 
and whose activity orchestrates cell growth 
mainly through the inhibition of autophagy 
and the activation of protein synthesis.3 A 
large body of evidence indicates that reduced 
levels of mTOR activity favor organismal and 
cellular longevity, and the small drug com-
pound rapamycin has been instrumental for 
the consolidation of this concept thanks to its 
ability to inhibit mTOR. in particular, chronic 
administration of rapamycin extends the 
lifespan of mice4 and, indeed, rapamycin is 
the only known compound able to increase 
Dissecting the role of mTOR complexes in cellular senescence
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longevity in mammals. Cellular senescence 
is a stress response that disables the prolif-
erative capacity of cells while maintaining 
their viability,5 and there is evidence that 
cellular senescence and organismal aging 
share some mechanistic principles. notably, 
contemporaneous to the description of the 
anti-aging activity of rapamycin in mice, it 
was also reported by Blagosklonny and col-
laborators that rapamycin delays cellular 
Although the two processes have distinct 
functions, recent work from Cambridge has 
determined that activation of autophagy is 
both typical of and, in some cases, sufficient 
to induce senescent transformation, and that 
inhibition of autophagy delays the acquisition 
of senescence.1
senescent cells are resistant to apoptotic 
signaling and are known to accumulate in 
many tissues during aging. interestingly, 
significant numbers are frequently found in 
close proximity to benign tumors. This colo-
calization has traditionally been seen as a 
result of senescence programs acting suc-
cessfully to terminate early-stage tumorigen-
esis. However, two studies2,3 published in 
this issue of Cell Cycle propose a different 
explanation, presenting compelling evidence 
for a direct metabolic link between neo-
plastic cells and the senescent fibroblasts 
surrounding the tumor. Analysis of clinical 
data indicates that a high level of autophagy 
and senescence in the stroma induced in 
vivo, particularly through hydrogen peroxide 
secretion by the tumor, correlates with poor 
prognosis in multiple cancers; however, the 
mechanism underlying this connection is not 
well understood.
To dissect the relationship between the 
autophagic state and tumor growth, hTeRT-
immortalized fibroblast cultures were trans-
formed with BniP3, cathepsin B or ATG16L1. 
each of the three genes employed was inde-
pendently able to support a state of constitu-
tively upregulated autophagy, as determined 
by a panel of biomarkers including downregu-
lation of the membrane protein caveolin-1.
Loss of caveolin-1—which alone is suffi-
cient to induce autophagy in some cell types,4 
suggesting a feedforward cycle—has been 
shown to result in ligand-independent activa-
tion of the TGFbeta pathway, with a particu-
larly prominent upregulation of connective 
tissue growth factor (CTGF). The authors dem-
onstrate a key intracellular role for CTGF in 
inducing and supporting the chronic autopha-
gic state, independent of its well-established 
role in enhancing extracellular matrix depo-
sition. specifically, CTGF overexpression is 
shown to promote HiF-1a signaling, result-
ing in increased transcription of glycolytic 
enzymes and components of the autophagic 
pathway.
The authors hypothesize that chronic 
autophagy, and particularly mitophagy, even-
tually results in a failure of mitochondrial 
respiration and a switch to predominantly 
aerobic glycolysis. As a result, the fibroblast 
produces a surplus of high-energy intermedi-
ates, including L-lactate and 3-hydroxy-butyr-
ate, which escape into the microenvironment 
and are taken up by nearby tumor cells as a 
supplemental energy source. The magnitude 
of this nutrient transfer is shown to be signifi-
cant, promoting experimental tumor growth 
by around 50–100%; surprisingly, metastasis 
rates are increased even more profoundly (up 
to 11-fold for ATG16L1-induced fibroblasts).
The accumulation of permanently senes-
cent cells over time is a well-established 
mechanism of systemic aging, contributing to 
the increased incidence of a number of con-
ditions—osteoarthritis, atherosclerosis, pros-
tatic hyperplasia, metabolic syndrome and 
cancer among them.5 The secretion of a panel 
of inflammatory mediators, the “senescence-
associated secretory phenotype,” or sAsP, is 
the best-characterized mediator of the patho-
logical effects observed, although it is not 
a universal feature of p16inK4a-senescent cell 
populations.6
Although senescence is not always an irre-
versible phenotype, its undeniably important 
role in tumor suppression makes attempts to 
therapeutically reverse it, such as telomerase-
activating drugs, particularly fraught. we have 
for some time advocated the more straight-
forward approach of selectively destroying 
(and, where necessary, replacing) senescent 
cells,7 and we are delighted to confirm that this 
approach has recently been shown to have 
significant rejuvenating effects in mice.8
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senescence induced by chemical stresses.6 
Chemically induced senescence is a well-
accepted model to study cellular senescence, 
but the question still remained whether rep-
licative and oncogene-induced senescence 
are also delayed by rapamycin. Replicative 
senescence results after extensive prolifera-
tion of cells in vitro, and it is considered the 
most relevant type of cellular senescence in 
relation to organismal aging.5 On the other 
hand, oncogene-induced senescence is rel-
evant for tumor suppression.5 These pending 
questions are now answered in the accompa-
nying reports, where it is demonstrated that 
rapamycin impairs replicative senescence in 
human1 and rodent2 cells, as well as onco-
gene-induced senescence.1 This satisfactorily 
extends the longevity activity of rapamycin 
to in vitro cultured cells and validates cellular 
senescence as a model to study organismal   
aging in relation to the mTOR pathway.
Dissecting the mTOR Complexes
An important consideration regarding mTOR 
kinase derives from the fact that it assem-
bles into two distinct multiprotein complexes 
named mTORC1 and mTORC2.3 To add further 
complexity, the inhibitory effect of rapamy-
cin on these two complexes depends on the 
dose and duration of the treatment. in gen-
eral, short treatments with rapamycin at low 
doses produce partial inhibition of mTORC1 
(and activation of mTORC2 as a result of the 
attenuation of the negative feedback loop that 
connects mTORC1 with mTORC2), whereas 
chronic treatment or high doses can inhibit 
both mTORC1 and mTORC2.3 in this complex 
scenario, it is not obvious whether the effects 
of rapamycin on organismal and cellular lon-
gevity are mediated by mTORC1, mTORC2 or 
both. An initial clue came from the observa-
tion that female mice lacking s6K1, a key 
substrate of mTORC1 (but not of mTORC2), 
have an increased longevity.7 This has been 
further supported by the report this year that 
female mice doubly heterozygous in mTOR 
and mLsT8 are partially deficient in mTORC1 
activity (but not in mTORC2 activity) and also 
present an extended lifespan.8 The molecular 
basis for the selective deficit in mTORC1 activ-
ity is not fully understood, because mLsT8 is 
common to both mTORC1 and mTORC2 com-
plexes, although a simple explanation could 
be their differential affinity for mLsT8. The 
emerging central role of mTORC1 inhibition 
in longevity is now complete thanks to the 
accompanying report by sun and collabora-
tors.1 in this paper, the authors demonstrate 
that selective inhibition of mTORC1, but not 
of mTORC2, impairs replicative and oncogene-
induced senescence (Fig. 1).1
Implications
These two new papers extend and solidify 
the anti-aging activity of rapamycin through 
inhibition of mTORC1.1,2 A point of worry is the 
inhibition of oncogene-induced senescence 
by rapamycin, which could suggest a pro-
tumorigenic effect of rapamycin. This concern, 
however, is mitigated by the fact that chronic 
treatment of mice with rapamycin does not 
produce an increase in spontaneous tumors.4 
nonetheless, rapamycin is not without unde-
sirable effects, due to its pro-diabetic activity.9 
The pro-diabetic activity of rapamycin is now 
known to be due to the inhibition of mTORC2 
(and not to the inhibition of mTORC1).8 in this 
state of affairs, the identification of rapamycin 
analogs highly selective for mTORC1 inhibition 
holds the promise of a more potent anti-aging 
activity.
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Figure 1. inhibition of mTORC1, but not of 
mTORC2, promotes cellular and organismal 
longevity.